SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir (PLTR) is surging after reporting strong earnings that significantly exceeded revenue expectations and providing robust 2026 guidance, particularly for its U.S. commercial sector, which is fueling community discussion around a potential short squeeze and high price targets amid ongoing valuation debates.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its highly engaged community champions the "OG meme" narrative, positioning Rage Comics as a foundational "meme reset" for the crypto market. Enthusiasts demonstrate strong conviction, actively building an ecosystem with platforms like RageMaker and RageGames, urging others to "Return to the Memes" and "Rage On" to assert dominance.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

The fintech community is buzzing with extreme speculation ahead of PayPal's earnings report, as a deeply divided sentiment pits those predicting further declines against proponents highlighting its massively oversold valuation, strong cash flow, and aggressive buybacks. Many also point to perceived institutional manipulation as the stock approaches multi-year lows before the key announcement.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXP Semiconductors is a trending topic after its latest earnings report, which presented mixed results and a cautious outlook, prompting a debate among investors. The community is weighing concerns about a potential broader "chip glut" against NXP's strategic growth in the automotive sector and innovative solutions for AI and quantum cryptography.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

PSLV is trending as the community actively discusses an intensifying global silver supply squeeze, fueled by reports of export restrictions and significant premiums for physical metal in Eastern markets compared to Western paper prices. This has led to strong investor accumulation, with many viewing recent volatility as a strategic buying opportunity amidst widespread speculation of market manipulation and an impending repricing of silver.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Proposed near-flat Medicare Advantage rates for 2027 and a subsequent Morgan Stanley downgrade have triggered a sharp selloff in Humana and the broader healthcare sector. The community is actively debating whether this decline to multi-year lows presents a deep value opportunity, given the company's strong cash position and potential for revised rates, or a justified repricing for its high reliance on Medicare Advantage.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is trending following its recent Q2 earnings beat and optimistic guidance, which analysts are reacting positively to amidst the ongoing AI-driven memory supercycle. Community conversations highlight the company's strong position in data storage, its ties to the surging SanDisk, and a debate around potential undervaluation versus concerns about the sector's rapid ascent.

ARK Investment Management LLC - ARK Innovation ETF

ARK Innovation ETF

ARKK is trending amidst intense community debate over Cathie Wood's active trading, particularly significant sales of Tesla shares alongside new buys in diverse innovation stocks, as investors weigh the fund's speculative growth strategy against rising "risk-off" sentiment for high-beta assets.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk ($SNDK) is experiencing a massive rally driven by blowout earnings that significantly surpassed expectations and aggressive price target upgrades from analysts. The community is fiercely debating whether the surge is a justified "monster" run fueled by insatiable AI memory demand or an unsustainable "bubble" fueled by market manipulation.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending ahead of its Q4 earnings report, with community debate centered on whether strong ad revenue and the strategic spin-off of its AR glasses division can overcome concerns about consistent unprofitability, significant leadership criticism, and the broader sector's regulatory challenges regarding youth usage.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of ZyVersa Therapeutics surged Wednesday, drawing heavy attention from retail investors after the company unveiled new plans to position its inflammasome ASC inhibitor, IC 100, as an adjunct to GLP-1 receptor agonists in addressing obesity-related cardiometabolic complications.The stock closed up&nbsp;over 24% at $0.68 on Wednesday before paring gains in after-hours trading, falling 12.38% to $0.60.In a shareholder letter, CEO Stephen C. Glover outlined a strategy to target inflammation-driven pathways that remain unaddressed by GLP-1 agonists such as semaglutide.&nbsp;While these drugs have transformed obesity treatment by inducing significant weight loss, Glover pointed to high discontinuation rates — up to 85% within two years among non-diabetic patients—and side effects including muscle loss and gastrointestinal issues as key limitations.“While GLP-1 agonists have revolutionized obesity treatment, significant unmet medical needs remain,” Glover wrote.ZyVersa’s IC 100 targets ASC and ASC specks, which play a central role in initiating and perpetuating inflammasome activation.&nbsp;Unlike most inflammasome inhibitors in development that target NLRP3, IC 100 is designed to broadly inhibit several inflammasomes implicated in obesity, insulin resistance, and diabetic nephropathy, including AIM2, NLRP1, NLRC4, and others.Preclinical studies cited by the company demonstrated that IC 100 reduced inflammation and plaque formation in an ApoE knockout model of atherosclerosis, lowered fasting blood glucose in diabetic kidney disease models, and suppressed key proinflammatory cytokines such as IL-1β, IL-18, and IL-6.ZyVersa said it will initiate a preclinical study combining IC 100 with semaglutide in H1 2025, file an Investigational New Drug (IND) application in H2 2025, and begin Phase 1 clinical trials in H1 2026 focusing on overweight individuals with cardiometabolic risk factors.Retail sentiment surged on Stocktwits, where message volume was marked “extremely high” and sentiment labeled “extremely bullish.”&nbsp;One user speculated the stock could rally to $2, while another suggested it looked “set up nicely” to retest the $1.05 pre-market high.<stembedurl>https://stocktwits.com/Netplus1/message/613838869</stembedurl><stembedurl>https://stocktwits.com/Chrismg8/message/613837620</stembedurl>Shares of Zyversa have fallen 37.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps

ZyVersa's IC 100 strategy focuses on targeting inflammasome-driven inflammation to enhance weight loss and improve metabolic function in obesity patients. 

Equity

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

ZyVersa Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMD earnings on Tuesday?

ZVSA
ZyVersa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings:

Historical Earnings

Latest ZVSA News

ZVSAZyVersa Therapeutics Inc